Samil Pharmaceutical News Today

HANOI, Vietnam -- Vietnam sees South Korea as a “good peer” in its plan to achieve developed-country status by 2045, according to Nguyen Anh Tuan, the deputy director general at the Foreign Investment Agency under Vietnam’s Ministry of Planning and Investment. “We plan to grow our economy to be a developing country with the GDP per capita in the group of the high-middle income by the year 2030...

Press Release Nicox Raises €10 Million in Private PlacementNet proceeds from the private placement to extend the cash runway to mid-May 2024Warrants to be issued in the private placement could provide

Press Release Nicox Raises €10 Million in Private PlacementNet proceeds from the private placement to extend the cash runway to mid-May 2024Warrants to be issued in the private placement could provide

Press ReleaseNicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones NCX 470...

Press ReleaseNicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones NCX 470 Mont Blanc Phase 3 clinical

Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones - read this article along with other careers information, tips and advice on BioSpace

Press ReleaseNicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China ZERVIATE (cetirizine ophthalmic solution), 0.24% was non-inferior to comparator

Press ReleaseNicox European Patent Seals ZERVIATE Major Market Coverage to 2030 Patent coverage for ZERVIATE (cetirizine ophthalmic solution), 0.24% in Europe until 2030 January 5, 2022 - release

® Agreement Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE ® (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full adva...

Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico TM to Mexico Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the signature of an exclusive license agreement with Laboratorios Grin, a wholly-owned subsidiary of Lupin Limited, for the registration and commercialization of ZERVIATE TM (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in...